Wachter, Rolf

[["dc.bibliographiccitation.firstpage","540"],["dc.bibliographiccitation.issue","6"],["dc.bibliographiccitation.journal","Biomarkers"],["dc.bibliographiccitation.lastpage","550"],["dc.bibliographiccitation.volume","23"],["dc.contributor.author","Baldassarri, Flavia"],["dc.contributor.author","Schwedhelm, Edzard"],["dc.contributor.author","Atzler, Dorothee"],["dc.contributor.author","Böger, Rainer H."],["dc.contributor.author","Cordts, Kathrin"],["dc.contributor.author","Haller, Bernhard"],["dc.contributor.author","Pressler, Axel"],["dc.contributor.author","Müller, Stephan"],["dc.contributor.author","Suchy, Christiane"],["dc.contributor.author","Wachter, Rolf"],["dc.contributor.author","Düngen, Hans-Dirk"],["dc.contributor.author","Hasenfuss, Gerd"],["dc.contributor.author","Pieske, Burkert"],["dc.contributor.author","Halle, Martin"],["dc.contributor.author","Edelmann, Frank"],["dc.contributor.author","Duvinage, André"],["dc.date.accessioned","2020-12-10T18:15:03Z"],["dc.date.available","2020-12-10T18:15:03Z"],["dc.date.issued","2018"],["dc.identifier.doi","10.1080/1354750X.2018.1460762"],["dc.identifier.eissn","1366-5804"],["dc.identifier.issn","1354-750X"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/74724"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.title","Relationship between exercise intervention and NO pathway in patients with heart failure with preserved ejection fraction"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","2296"],["dc.bibliographiccitation.issue","9"],["dc.bibliographiccitation.journal","Biomedicines"],["dc.bibliographiccitation.volume","10"],["dc.contributor.affiliation","Lechner, Katharina; 1Rehabilitation and Sports Medicine, Department of Prevention, School of Medicine, Technical University of Munich, 80992 Munich, Germany"],["dc.contributor.affiliation","von Schacky, Clemens; 4Omegametrix, Martinsried, 82152 Munich, Germany"],["dc.contributor.affiliation","Scherr, Johannes; 1Rehabilitation and Sports Medicine, Department of Prevention, School of Medicine, Technical University of Munich, 80992 Munich, Germany"],["dc.contributor.affiliation","Lorenz, Elke; 3Kardiologie, Deutsches Herzzentrum München, 80636 Munich, Germany"],["dc.contributor.affiliation","Bock, Matthias; 2DZHK (German Centre for Cardiovascular Research), Partner Site Munich, Munich Heart Alliance, 80336 Munich, Germany"],["dc.contributor.affiliation","Lechner, Benjamin; 6Department of Internal Medicine IV, Ludwig-Maximilians University, 80336 Munich, Germany"],["dc.contributor.affiliation","Haller, Bernhard; 7Institute of AI and Informatics in Medicine, Klinikum rechts der Isar, Technische Universität München, 81675 Munich, Germany"],["dc.contributor.affiliation","Krannich, Alexander; 8Charité, Universitätsmedizin Berlin, 10117 Berlin, Germany"],["dc.contributor.affiliation","Halle, Martin; 1Rehabilitation and Sports Medicine, Department of Prevention, School of Medicine, Technical University of Munich, 80992 Munich, Germany"],["dc.contributor.affiliation","Wachter, Rolf; 9Clinic and Policlinic for Cardiology, University Hospital Leipzig, 04103 Leipzig, Germany"],["dc.contributor.affiliation","Duvinage, André; 1Rehabilitation and Sports Medicine, Department of Prevention, School of Medicine, Technical University of Munich, 80992 Munich, Germany"],["dc.contributor.affiliation","Edelmann, Frank; 12Department of Cardiology, Charité, Universitätsmedizin Berlin, 10117 Berlin, Germany"],["dc.contributor.author","Lechner, Katharina"],["dc.contributor.author","von Schacky, Clemens"],["dc.contributor.author","Scherr, Johannes"],["dc.contributor.author","Lorenz, Elke"],["dc.contributor.author","Bock, Matthias"],["dc.contributor.author","Lechner, Benjamin"],["dc.contributor.author","Haller, Bernhard"],["dc.contributor.author","Krannich, Alexander"],["dc.contributor.author","Halle, Martin"],["dc.contributor.author","Wachter, Rolf"],["dc.contributor.author","Edelmann, Frank"],["dc.contributor.author","Duvinage, André"],["dc.contributor.editor","Drozd, Arleta"],["dc.date.accessioned","2022-10-04T10:21:47Z"],["dc.date.available","2022-10-04T10:21:47Z"],["dc.date.issued","2022"],["dc.date.updated","2022-11-11T13:13:12Z"],["dc.description.abstract","Background: Circulating long-chain (LCSFAs) and very long-chain saturated fatty acids (VLSFAs) have been differentially linked to risk of incident heart failure (HF). In patients with heart failure with preserved ejection fraction (HFpEF), associations of blood SFA levels with patient characteristics are unknown. Methods: From the Aldo-DHF-RCT, whole blood SFAs were analyzed at baseline in n = 404 using the HS-Omega-3-Index® methodology. Patient characteristics were 67 ± 8 years, 53% female, NYHA II/III (87%/13%), ejection fraction ≥50%, E/e’ 7.1 ± 1.5; and median NT-proBNP 158 ng/L (IQR 82–298). Spearman´s correlation coefficients and linear regression analyses, using sex and age as covariates, were used to describe associations of blood SFAs with metabolic phenotype, functional capacity, cardiac function, and neurohumoral activation at baseline and after 12-month follow-up (12 mFU). Results: In line with prior data supporting a potential role of de novo lipogenesis-related LCSFAs in the development of HF, we showed that baseline blood levels of C14:0 and C16:0 were associated with cardiovascular risk factors and/or lower exercise capacity in patients with HFpEF at baseline/12 mFU. Contrarily, the three major circulating VLSFAs, lignoceric acid (C24:0), behenic acid (C22:0), and arachidic acid (C20:0), as well as the LCSFA C18:0, were broadly associated with a lower risk phenotype, particularly a lower risk lipid profile. No associations were found between cardiac function and blood SFAs. Conclusions: Blood SFAs were differentially linked to biomarkers and anthropometric markers indicative of a higher-/lower-risk cardiometabolic phenotype in HFpEF patients. Blood SFA warrant further investigation as prognostic markers in HFpEF. One Sentence Summary: In patients with HFpEF, individual circulating blood SFAs were differentially associated with cardiometabolic phenotype and aerobic capacity."],["dc.description.sponsorship","German Foundation of Heart Research"],["dc.description.sponsorship","Federal Ministry of Education and research"],["dc.identifier.doi","10.3390/biomedicines10092296"],["dc.identifier.pii","biomedicines10092296"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/114500"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-600"],["dc.publisher","MDPI"],["dc.relation.eissn","2227-9059"],["dc.rights","Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/)."],["dc.title","Saturated Fatty Acid Blood Levels and Cardiometabolic Phenotype in Patients with HFpEF: A Secondary Analysis of the Aldo-DHF Trial"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","Clinical Research in Cardiology"],["dc.contributor.author","Lechner, Katharina"],["dc.contributor.author","Scherr, Johannes"],["dc.contributor.author","Lorenz, Elke"],["dc.contributor.author","Lechner, Benjamin"],["dc.contributor.author","Haller, Bernhard"],["dc.contributor.author","Krannich, Alexander"],["dc.contributor.author","Halle, Martin"],["dc.contributor.author","Wachter, Rolf"],["dc.contributor.author","Duvinage, André"],["dc.contributor.author","Edelmann, Frank"],["dc.date.accessioned","2021-10-01T09:58:53Z"],["dc.date.available","2021-10-01T09:58:53Z"],["dc.date.issued","2021"],["dc.description.abstract","Abstract Objectives To evaluate associations of omega-3 fatty acid (O3-FA) blood levels with cardiometabolic risk markers, functional capacity and cardiac function/morphology in patients with heart failure with preserved ejection fraction (HFpEF). Background O3-FA have been linked to reduced risk for HF and associated phenotypic traits in experimental/clinical studies. Methods This is a cross-sectional analysis of data from the Aldo-DHF-RCT. From 422 patients, the omega-3-index (O3I = EPA + DHA) was analyzed at baseline in n  = 404 using the HS-Omega-3-Index ® methodology. Patient characteristics were; 67 ± 8 years, 53% female, NYHA II/III (87/13%), ejection fraction ≥ 50%, E / e ′ 7.1 ± 1.5; median NT-proBNP 158 ng/L (IQR 82–298). Pearson’s correlation coefficient and multiple linear regression analyses, using sex and age as covariates, were used to describe associations of the O3I with metabolic phenotype, functional capacity, echocardiographic markers for LVDF, and neurohumoral activation at baseline/12 months. Results The O3I was below (< 8%), within (8–11%), and higher (> 11%) than the target range in 374 (93%), 29 (7%), and 1 (0.2%) patients, respectively. Mean O3I was 5.7 ± 1.7%. The O3I was inversely associated with HbA1c ( r  = − 0.139, p  = 0.006), triglycerides-to-HDL-C ratio ( r  = − 0.12, p  = 0.017), triglycerides ( r  = − 0.117, p  = 0.02), non-HDL-C ( r  = − 0.101, p  = 0.044), body-mass-index ( r  = − 0.149, p  = 0.003), waist circumference ( r  = − 0.121, p  = 0.015), waist-to-height ratio ( r  = − 0.141, p  = 0.005), and positively associated with submaximal aerobic capacity ( r  = 0.113, p  = 0.023) and LVEF ( r  = 0.211, p  < 0.001) at baseline. Higher O3I at baseline was predictive of submaximal aerobic capacity ( β  = 15.614, p  < 0,001), maximal aerobic capacity ( β  = 0.399, p  = 0.005) and LVEF ( β  = 0.698, p  = 0.007) at 12 months. Conclusions Higher O3I was associated with a more favorable cardiometabolic risk profile and predictive of higher submaximal/maximal aerobic capacity and lower BMI/truncal adiposity in HFpEF patients. Graphic abstract Omega-3 fatty acid blood levels are inversely associated with cardiometabolic risk factors in HFpEF patients. Higher O3I was associated with a more favorable cardiometabolic risk profile and aerobic capacity (left) but did not correlate with echocardiographic markers for left ventricular diastolic function or neurohumoral activation (right). An O3I-driven intervention trial might be warranted to answer the question whether O3-FA in therapeutic doses (with the target O3I 8–11%) impact on echocardiographic markers for left ventricular diastolic function and neurohumoral activation in patients with HFpEF. This figure contains modified images from Servier Medical Art ( https://smart.servier.com ) licensed by a Creative Commons Attribution 3.0 Unported License."],["dc.description.abstract","Abstract Objectives To evaluate associations of omega-3 fatty acid (O3-FA) blood levels with cardiometabolic risk markers, functional capacity and cardiac function/morphology in patients with heart failure with preserved ejection fraction (HFpEF). Background O3-FA have been linked to reduced risk for HF and associated phenotypic traits in experimental/clinical studies. Methods This is a cross-sectional analysis of data from the Aldo-DHF-RCT. From 422 patients, the omega-3-index (O3I = EPA + DHA) was analyzed at baseline in n  = 404 using the HS-Omega-3-Index ® methodology. Patient characteristics were; 67 ± 8 years, 53% female, NYHA II/III (87/13%), ejection fraction ≥ 50%, E / e ′ 7.1 ± 1.5; median NT-proBNP 158 ng/L (IQR 82–298). Pearson’s correlation coefficient and multiple linear regression analyses, using sex and age as covariates, were used to describe associations of the O3I with metabolic phenotype, functional capacity, echocardiographic markers for LVDF, and neurohumoral activation at baseline/12 months. Results The O3I was below (< 8%), within (8–11%), and higher (> 11%) than the target range in 374 (93%), 29 (7%), and 1 (0.2%) patients, respectively. Mean O3I was 5.7 ± 1.7%. The O3I was inversely associated with HbA1c ( r  = − 0.139, p  = 0.006), triglycerides-to-HDL-C ratio ( r  = − 0.12, p  = 0.017), triglycerides ( r  = − 0.117, p  = 0.02), non-HDL-C ( r  = − 0.101, p  = 0.044), body-mass-index ( r  = − 0.149, p  = 0.003), waist circumference ( r  = − 0.121, p  = 0.015), waist-to-height ratio ( r  = − 0.141, p  = 0.005), and positively associated with submaximal aerobic capacity ( r  = 0.113, p  = 0.023) and LVEF ( r  = 0.211, p  < 0.001) at baseline. Higher O3I at baseline was predictive of submaximal aerobic capacity ( β  = 15.614, p  < 0,001), maximal aerobic capacity ( β  = 0.399, p  = 0.005) and LVEF ( β  = 0.698, p  = 0.007) at 12 months. Conclusions Higher O3I was associated with a more favorable cardiometabolic risk profile and predictive of higher submaximal/maximal aerobic capacity and lower BMI/truncal adiposity in HFpEF patients. Graphic abstract Omega-3 fatty acid blood levels are inversely associated with cardiometabolic risk factors in HFpEF patients. Higher O3I was associated with a more favorable cardiometabolic risk profile and aerobic capacity (left) but did not correlate with echocardiographic markers for left ventricular diastolic function or neurohumoral activation (right). An O3I-driven intervention trial might be warranted to answer the question whether O3-FA in therapeutic doses (with the target O3I 8–11%) impact on echocardiographic markers for left ventricular diastolic function and neurohumoral activation in patients with HFpEF. This figure contains modified images from Servier Medical Art ( https://smart.servier.com ) licensed by a Creative Commons Attribution 3.0 Unported License."],["dc.identifier.doi","10.1007/s00392-021-01925-9"],["dc.identifier.pii","1925"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/90166"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-469"],["dc.relation.eissn","1861-0692"],["dc.relation.issn","1861-0684"],["dc.title","Omega-3 fatty acid blood levels are inversely associated with cardiometabolic risk factors in HFpEF patients: the Aldo-DHF randomized controlled trial"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]